| Literature DB >> 17431567 |
Abstract
Laryngeal dystonia (spasmodic dysphonia) is a movement disorder characterised by involuntary contractions of the laryngeal muscles involved in vocalisation. The introduction of botulinum toxin (BTX) in the treatment of laryngeal dystonia had a major clinical impact due to the striking improvement of symptoms. Most patients with severe types of spasmodic dysphonia are treated with injections of botulinum toxin type A. For patients with a resistance against type A toxin there is a new hypercleaned type A toxin or type B available. Research on type F toxin is also underway. In this article, the history of botulinum toxin, its therapeutic activity and possibilities for its use are described.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17431567 DOI: 10.1007/s00106-007-1553-5
Source DB: PubMed Journal: HNO ISSN: 0017-6192 Impact factor: 1.284